Clinical trials
Resectable Pancreatic Ductal Adenocarcinoma clinical trials
Below are recruiting resectable pancreatic ductal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 98 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05688215RecruitingPhase 1/Phase 2
Zimberelimab and quemliclustat with chemotherapy for pancreatic cancer
This trial studies how well zimberelimab and quemliclustat work together with standard chemotherapy for people with borderline resectable or locally advanced pancreatic cancer. It may help shrink the tumor and make treatment more effective before or around the time surgery is considered for some patients.
Los Angeles, CaliforniaAges 18 years+ - NCT05526443Recruiting
Registry study for advanced pancreatic cancer treatment patterns
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
Graz, StyriaAges 18 years+ - NCT05518903RecruitingPhase 2
Scan test to see tumor-support cells in pancreatic cancer
This trial tests a special imaging scan (a PET/CT with a tracer called 68Ga-FAPI-46) to look at “cancer-support” cells in people with localized pancreatic ductal adenocarcinoma. It may help doctors better understand the tumor and how it responds before surgery after initial treatment.
Rochester, MinnesotaAges 18 years+ - NCT05296421Recruiting
Biopsy study during pancreatic cancer surgery to guide treatment
This study looks at specific body chemistry pathways in pancreatic cancer tissue to better understand what may help treatment work. If you are having pancreatic surgery, the researchers will take extra small tissue samples during the operation to study tumor and normal tissue.
Livingston, New JerseyAges 18 years+ - NCT05132244Recruiting
Monitoring blood sugar levels in people starting pancreatic cancer treatment
This study looks at how well blood sugar (glucose) levels can be monitored and managed in people with pancreatic cancer who are starting their first treatment. It aims to understand if careful glucose management can improve well-being and possibly treatment outcomes.
Vancouver, British ColumbiaAges 18 years+ - NCT05132504RecruitingPhase 2
Pre-surgery chemotherapy and immunotherapy for operable pancreatic cancer
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Houston, TexasAges 18 years+ - NCT04875325Enrolling by invitation
Monitoring for pancreatic cancer coming back after surgery
This study looks at a standardized plan for check-ups to detect pancreatic cancer returning after surgery. It may help find recurrence earlier and guide what follow-up care you might need next.
Nijmegen, GelderlandAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT03977233RecruitingPhase 2
Biopsies and FOLFIRINOX for non-metastatic pancreatic cancer
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Chapel Hill, North CarolinaAges 18–99 - NCT04406831Recruiting
Testing microRNA for pancreatic cancer diagnosis and treatment response
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
Norwalk, ConnecticutAges 18 years+ - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+ - NCT03608631RecruitingPhase 1/Phase 2
Exosome treatment for KRAS-mutated metastatic pancreatic cancer
This Phase 1/2 study tests an investigational treatment made from “exosomes” for people with metastatic pancreatic cancer that has a specific KRAS mutation (KRAS G12D). It aims to see if this treatment can control the cancer and is safe for patients whose cancer has grown or stayed the same after prior chemotherapy.
Houston, TexasAges 18 years+ - NCT04926467RecruitingPhase 2
Chemo plus anakinra for pancreatic cancer
This Phase 2 study tests whether adding anakinra (an immune signal blocker) to standard chemotherapy can improve outcomes for some people with pancreatic ductal adenocarcinoma. It’s mainly for adults with stage I–III disease who have enough organ function and are able to come in for treatment and follow-up.
Dallas, TexasAges 18 years+ - NCT05529940RecruitingPhase 3
FOLFIRINOX around surgery for resectable pancreatic cancer
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
SeoulAges 19–80 - NCT06966440Recruiting
MRD-Guided Chemotherapy After Pancreatic Cancer Surgery
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
ShanghaiAges 18–75 - NCT06349278Recruiting
Surgery for pancreatic cancer with limited liver spread after chemo
This trial is for people with pancreatic cancer that has spread to the liver (3 spots or fewer). It tests whether removing both the original tumor and the liver spots after a specific chemotherapy (FOLFIRINOX) can be helpful. You may be eligible if the chemo shrinks the tumors enough and you are healthy enough for surgery.
Québec, QuebecAges 18 years+ - NCT02869802Recruiting
Study types of pancreatic cancer using tumor gene testing
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
Calgary, AlbertaAges 18 years+ - NCT05802407Recruiting
ctDNA blood test monitoring after pancreatic cancer surgery
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
BeijingAges 18 years+ - NCT04622423Recruiting
Advanced therapies for colon or pancreas liver metastases
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
Milan, MilanAges 18 years+ - NCT07255001Recruiting
How muscle strength tests can help track health in pancreatic cancer
This study uses hand-grip strength tests and CT scans to understand how pancreatic cancer affects your muscles and quality of life. It may help doctors better support your strength and well-being during treatment.
Vancouver, British ColumbiaAges 18 years+ - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT05919238RecruitingPhase 1
Padeliporfin treatment for non-removable pancreatic cancer
This Phase 1 study tests a new cancer treatment called padeliporfin given through a special catheter to treat pancreatic ductal adenocarcinoma that cannot be removed by surgery. It aims to see how safe the treatment is and whether it can help control the tumor in people who are not surgical candidates.
Duarte, CaliforniaAges 18 years+ - NCT04881487Recruiting
Radiation treatment for local pancreatic cancer recurrence
This trial looks at additional treatment using a special type of focused radiation (stereotactic body radiation therapy) for pancreatic cancer that has come back only in the same area after surgery. It may help by controlling the local recurrence and possibly improving outcomes for people whose cancer has not spread elsewhere.
Amsterdam, North HollandAges 18 years+
Hear when a new Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable pancreatic ductal adenocarcinoma?
- Yes. Clin2 currently lists 98 recruiting resectable pancreatic ductal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable pancreatic ductal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.